Liraglutide's impact on angiogenesis biomarkers in Type 2 Diabetes patients evaluated in Phase 4 trial

Type 2 Diabetes (T2D) is a chronic metabolic disorder often leading to severe micro- and macrovascular complications, including impaired vascular integrity. Current standard-of-care treatments primarily focus on glycemic control, but a deeper understanding of their impact on vascular health, particularly angiogenesis, is crucial. GLP-1 receptor agonists are effective T2D therapies, yet their specific role in regulating vascular integrity and angiogenic processes remains underexplored. This gap highlights the need to evaluate how these agents influence key angiogenesis biomarkers.

This Phase 4, randomized, active-comparator trial enrolled 50 patients with Type 2 Diabetes. Participants were assigned to receive either Liraglutide 1.2 mg once daily subcutaneous injection for 1 month (4 weeks) or an add-on oral antidiabetic medication (metformin or sulfonylurea) as an active control. The primary objective was to evaluate the impact of one-month Liraglutide treatment on levels of ANGPT2 and ANGLPT4, as well as endothelial circulating progenitor cells, which are established angiogenesis biomarkers.

The provided abstract describes the study's design and objectives but does not present the actual findings or results from this completed Phase 4 clinical trial. It states that the study aimed to evaluate the impact of one-month Liraglutide treatment on angiogenesis biomarkers, specifically ANGPT2 and ANGLPT4 levels, and endothelial circulating progenitor cells in Type 2 Diabetes patients. Without the results, it is not possible to report specific numerical changes, statistical significances, or the observed effects of Liraglutide on these vascular markers. The abstract confirms the study's completion, but the outcomes regarding Liraglutide's influence on angiogenesis in this patient cohort are not detailed.